Kornimate/medical-research-clean huggingface dataset:
potential associated factors of uncontrolled hypertension

Conditions: Hypertension,Essential

Summary: the incidence and prevalence of hypertension is increasing while the controlled rate is extremely low in china. a substantial percentage of participants with uncontrolled hypertension are correctable if potential associated factors are identified and corrected. therefore, it is clinically relevant to investigate and identify these potential associated factors of uncontrolled hypertension so as to increase controlled rate and reduce hypertension-associated health and economic burdens in the future. investigators plan to conduct a prospective registry study in a single-center to initially investigate the potential associated factors of uncontrolled hypertension in cardiovascular outpatient department. furthermore, investigators plan to evaluate the effects of potential associated factors correction on hypertension controlled rate and cardiovascular outcomes.


Eligibility criteria:
inclusion criteria: * clinic systolic and/or diastolic blood pressure above 140 and/or 90 mm hg treating with 3 different classes of anti-hypertensive drugs (not necessarily including diuretic). exclusion criteria: * known secondary hypertension, * pregnant women, * chronic kidney disease (ckd) 3 or higher, * has a history of connective tissue diseases, * has a history of any type of cancer, * cognitive disorder which could not finish home blood pressure monitoring, * has a history of coronary heart disease,ischemic stroke,transient ischemic attack or heart failure.

Keywords: hypertension essential hypertension blood pressure cardiovascular diseases
effect of hypoxia on cognitive assessment and cerebral activity in healthy volunteers

Conditions: Alteration of Cognitive Function; Hypoxia

Summary: the early assessment of new symptomatic drugs for alzheimer disease remains difficult because of the lack of predictive end-point. the use of a battery including different parameters could improve this early development. in healthy volunteers, to test the reverse effect of symptomatic drugs, it is necessary to induce transient and reversible cognitive impairment and cerebral activity changes by a challenge test. in this context, a transient hypoxia could be relevant.


Eligibility criteria:
inclusion criteria: * good health on the basis of the medical interview, physical examination and standard biology parameters. * right-handed * non-smoker * no cardiac nor pulmonary pathologies * no use of chronic treatment or psychotropic drugs or substances * bmi inferior to 25 kg/m2 * french speaker and able to understand the test instructions * informed consent form signed exclusion criteria: 1. subject with history or current brain disease (severe brain trauma, transient ischemic attack, stroke, epilepsy, cerebral tumor...) or retinal pathologies (including familial dmla) 2. subject with history of acute mountain sickness, high altitude cerebral edema or high altitude pulmonary edema 3. subject with other major medical or surgical history including coronaropathy and pulmonary arterial hypertension 4. subject with current chronic disease 5. subject with vascular or metabolic risk factor 6. subject with history of or current mental disease or addiction (mini) 7. subject with significant abnormality on biology 8. subject with significant abnormality on ecg 9. subject with significant abnormality on mri 10. subject with significant abnormality of electrical activities on eeg 11. subject with family history of young onset dementia 12. subject with family history of cardiac or pulmonary pathologies 13. subject with family history of chronic or severe neurological or mental disease (first degree relatives) 14. subject with claustrophobia or contraindication to mri 15. subject under guardianship 16. subject not covered by social security 17. subject participating in another clinical trial 18. subject with anxiety (stai-trait score t\> 51) or neuroticism personality (epi score n ≥13) 19. subject bearded or refusing to shave

Keywords: cognitive function hypoxia neurophysiological function effect of alzheimer disease symptomatic drugs healthy subjects
acetaminophen (apap) +/- oxycodone

Conditions: Musculoskeletal Pain

Summary: this is an emergency department based randomized study of oxycodone/ acetaminophen versus acetaminophen alone for patients with acute musculoskeletal pain refractory to ibuprofen


Eligibility criteria:
inclusion criteria: * acute musculoskeletal pain: any pain attributable to muscles, bones, joints, tendons, ligaments or supporting structures, as determined by the clinical team, of 10 days duration or less. prior to the onset of acute pain, patients cannot have experienced pain in the same body region during the prior six months * pain has to be described as moderate or severe, when the patient is asked if the pain is mild, moderate or severe in intensity exclusion criteria: * use of an non-steroidal anti-inflammatory drug within the previous six hours * use of acetaminophen within the previous six hours * use of an opioid within the previous ten days * chronic pain, defined as any pain on \>50% of days for at least 3 months prior to onset of acute pain * gout
the anti-fibrotic therapeutic effects of resveratrol for discharged covid-19 patients

Conditions: Covid-19

Summary: a randomized controlled trial (rct) will be conducted to evaluate the anti-fibrotic therapeutic effects of resveratrol on the clinical symptoms in discharged covid-19 patients.

the proposed study will be a randomized controlled trial (rct) to evaluate the anti-fibrotic therapeutic effects of resveratrol on the clinical symptoms in discharged covid-19 patients. the target population will be post-discharge patients recovering from covid-19. eligible participants will be recruited from the ongoing special chinese medicine program for discharged patients collaborated with hong kong hospital authority. thirty (30) participants will be randomly assigned to resveratrol group and placebo group with 1:1 ratio. the participants will receive six months of treatment (1 g, orally and once daily) and three months of follow-up. the total duration of the clinical study is 9 months. the study protocol will be submitted to the ethics committee for review and approval. participants will be enrolled and signed written informed consent.

Eligibility criteria:
inclusion criteria: * participants will be the patients aged 18-65 years old who have been previously diagnosed to be infected with covid-19 and discharged from local hospitals after treatment with western medicines, and with negative results from covid-19 virus detection. the subjects will be evaluated for potential pulmonary fibrosis and those who present with the condition resulting from covid-19 infection will be included. exclusion criteria: * participants will be excluded if they have one or more of the followings: 1) inability to communicate (e.g. cognitive impairment); 2) history of chinese medicine allergies; 3) incompetent in giving consent.

Keywords: rehabilitation chinese medicine randomized controlled trial
laparoscopic surgery for severe recto-vaginal endometriosis

Conditions: Endometriosis Rectovaginal Septum

Summary: to determine the quality of life following the radical excision of recto-vaginal endometriosis.

patients undergoing surgery for severe endometriosis with bowel involvement were asked to complete pre-operative and post operative questionnaires at 2, 6 and 12 months, then 5, 10, 15, 20 and 25 years post operatively. quality of life measured using the ehp-30 and eq-5d questionnaires. bowel symptoms were measured using giqli. dysmenorrhoea, dyspareunia, dyschezia and chronic pain were measured using a visual analogue scale.

Eligibility criteria:
inclusion criteria: * all women undergoing planned surgery for severe endometriosis with bowel involvement. exclusion criteria: * patients who declined to complete questionnaires for whatever reason and/or have their anonymous data analysed.
digital cognitive behavioral therapy for depressive disorders

Conditions: Depression; Anxiety

Summary: this study aims to explore the effectiveness of digital interventions combined with medication in the treatment of patients with depressive disorders. its main aim is to answer: can digital interventions combined with medication effectively alleviate symptoms of depression? the experiment will compare the effects of medication combined with digital interventions to those combined with online mental health education to evaluate their relative effectiveness. participants will be required to engage with the medication plus digital therapy for a duration of two months, and follow-up assessments will be conducted to evaluate the long-term effects of the treatments and monitor any changes in depressive symptoms.


Eligibility criteria:
inclusion criteria: 1. meets the diagnostic criteria for depression according to the dsm-5 (diagnostic and statistical manual of mental disorders, fifth edition), without psychotic symptoms, as recurrent outpatient or inpatient. 2. patients with a montgomery-asberg depression rating scale (madrs) score ≥ 22 before randomization. 3. age ≥ 18 and ≤ 65 years, regardless of gender. 4. understands the trial and signs the informed consent form. exclusion criteria: 1. meets criteria for other psychiatric disorders according to the dsm-5, including schizophrenia spectrum disorders, bipolar and related disorders, neurodevelopmental disorders, neurocognitive disorders, or depression due to substance and/or medication or other medical conditions. 2. history of substance and/or alcohol abuse within the past year. 3. significant risk of suicide (madrs item 10 score = 4). 4. difficulty or inability to communicate verbally, understand or follow instructions, or cooperate with treatment and assessment. 5. inability to use a smartphone. 6. deemed unsuitable for participation by the researcher.
alternate dosing - initiation of every 2 week epoetin alfa (procrit) in the treatment of anemia.

Conditions: Anemia; Kidney Diseases

Summary: the purpose of this study is to evaluate the hemoglobin response rate in subjects with anemia, associated with chronic kidney failure, after receiving epoetin alfa (procritâ®) every 2 weeks

this is a prospective study in non-dialysis subjects with anemia associated with chronic kidney disease. subjects will be enrolled from multiple centers in the united states. the primary objective of the study is to evaluate hemoglobin response rate. the secondary objectives include evaluating the time to when hemoglobin responds, indicated by the results of the hemoglobin blood levels, the change in hemoglobin over time, the transfusion requirements and change in quality of life measurements. these measurements asks for the subjects views about how one feels, activity and energy level, etc. the subjects are administered study drug every 2 weeks through study week 27 unless dosing is held or the subject withdraws from the study. each injection of study drug should not exceed 1 ml in volume.

Eligibility criteria:
inclusion criteria: * subjects with chronic kidney disease and a glomerular filtration rate within 10-60 ml/min/1.73m2 with no expected need for dialysis during the study * subjects with a hemoglobin less than 11 g/dl * subjects who have not received erythropoietic agents within 6 weeks before study entry * female subjects, with a reproductive potential, must have a negative urine pregnancy test within 7 days of the first dose of study drug. exclusion criteria: * subjects with poorly controlled high blood pressure (hypertension) - systolic \> 150 mm hg or diastolic \> 100 mm hg * known hypersensitivity to human albumin and/or mammalian cell-derived products * subjects receiving dialysis * subjects with a ferritin level \< 50 ng/ml, transferrin saturation \< 20% * subjects receiving chemotherapy for cancer within 1 month prior to study start or expected during study participation * pregnancy or lactation.

Keywords: anemia chronic kidney disease erythropoetin, epoetin alfa erythropoetin recombinant pre-dialysis
single low-dose primaquine efficacy and safety.

Conditions: Malaria

Summary: background: the world health organization has recommended addition of a 0.25 mg/kg single-dose primaquine (pq) to standard artemisinin-based combination therapy (act) for elimination of malaria in low transmission-settings and for containment in areas threatened by artemisinin resistance. however, pq metabolism is dependent on a highly polymorphic cytochrome p450 (cyp) 2d6 isoenzyme which probably compromises the drugs' safety and efficacy, particularly in individuals with reduced isoenzyme activity. this trial therefore, aims to assess the safety and efficacy of 0.25 mg/kg single-dose pq when added to standard artemether-lumefantrine regimen for clearance and sterilization of plasmodium falciparum gametocytes in patients with cyp450 2d6 reduced/null activity as compared to those with normal/increased enzyme activity. methods: on hundred and fifty-five children aged between 1 and 10 years and with uncomplicated p. falciparum malaria will be enrolled, treated with standard artemether-lumefantrine regimen plus a 0.25 mg/kg single-dose of pq and then followed up on days 0, 1, 2, 3, 7, 14, 21 and 28 for clinical and laboratory assessment. primaquine will be administered together with the first dose of artemether-lumefantrine. safety assessment will be performed using the primaquine roll out monitoring pharmacovigilance tool (prompt). gametocytes will be detected and quantified by microscopy and pfs25 mrna quantitative nucleic acid sequence based amplification (qt-nasba) on days 0 and 7. for a subset of 100 participants, post-treatment infectiousness will be assessed by mosquito feeding assays on day 7. the cyp2d6 status will be determined using a polymerase chain reaction (pcr) followed by a restriction fragment length polymorphism (rflp). the primary outcome will be the safety of single low-dose primaquine in patients with cyp2d6 reduced/null compared to those with normal/increased activity. expected outcomes: the findings will provide the much-needed information on the safety and efficacy of single low-dose primaquine for clearance and sterilization of p. falciparum gametocytes in individuals with reduced/null compared to those with normal/increased cyp450 2d6 isoenzyme activity prior to the implementation of the treatment policy particularly in africa.


Eligibility criteria:
inclusion criteria: * age from 1 to 10 years * weight ≥ 10 kg * body temperature ≥ 37.5°c or history of fever in the last 24 hours * microscopy confirmed p. falciparum mono-infection * parasitemia level of 2000 - 200000/µl * ability to swallow oral medication * ability and willingness to abide by the study protocol and the stipulated follow up visits * written proxy informed consent from a parent/guardian. exclusion criteria: * evidence of severe malaria or danger signs * known allergy to trial medicines * reported antimalarial intake ≤ 2 weeks * hemoglobin \< 5 g/dl * blood transfusion within last 90 days * febrile condition other than malaria * known underlying chronic or severe disease
biologic therapy in pediatric jia uveitis

Conditions: Juvenile Idiopathic Arthritis Associated Uveitis

Summary: juvenile idiopathic arthritis (jia) remains the most common systemic disorder associated with pediatric uveitis. studies estimate that 28-67% of patients with jia-associated uveitis develop ocular complications, with 12% developing poor visual outcome. the only means of improving long term effects of uveitis, is early and aggressive anti-inflammatory treatment, including biologics.

juvenile idiopathic arthritis (jia) remains, globally, the most common systemic disorder associated with pediatric uveitis consisting 75% of anterior uveitis cases (au)1. in a cohort study from cairo university pediatric hospital, jia accounted for 39% of all cases of pediatric uveitis (unpublished data). studies estimate that 28-67% of patients with jia-u develop ocular complications, with 12% developing poor visual outcome2,3,4. thus, early and aggressive anti-inflammatory treatment is the only means of improving long term effects of uveitis5-7. in 2019, the american college of rheumatology/arthritis foundation recommended, that in severe, active, chronic au or in the presence of sight-threatening complications, methotrexate (mtx) and a monoclonal antibody tumor necrosis factor inhibitor (tnfi) should be immediately administered8. biologic drugs act against specific cytokines or their receptors, in order to reduce tissue damage9. currently, infliximab, and adalimumab are the main tnf inhibitors available for children10 and are used in the treatment of refractory or chronic childhood uveitis 11,12 . our study aims to analyze the value and outcome of using biologics at abou el reesh, cairo university hospital, being a main tertiary referral center in egypt for children with jia-u.

Eligibility criteria:
inclusion criteria: * diagnosed jia according to rheumatological criteria with ocular affection * any type of arthritis (oligoarticular, polyarticular, systemic onset, ocular jia) * ana positive or negative * uncontrolled uveitis or frequent relapses exclusion criteria: * patients without definitive diagnosis as jia * jia patients on biologics without ocular affection (for systemic control) or with uveitis controlled without the use of biologics * patients without adequate duration for follow-up (less than 3 months) or lost follow up data * patients without available data prior to the start biologics (to compare control of the uveitis)

Keywords: biologics jia-u uveitis pediatrics adalimumab
electrical stimulation for respiratory and leg muscles impact on copd patients

Conditions: Chronic Obstructive Pulmonary Disease

Summary: electrical neuromuscular stimulation electrode patches will be applied over the intercostal respiratory muscles and leg muscles

electrical neuromuscular stimulation electrode patches will be applied over the intercostal respiratory muscles and leg muscles (placed superficially just below each knee, over the head of the fibula, in close proximity to the common peroneal nerve). active stimulation consisted of a ∼30-second ramp-up to the titrated intensity value at the start of stimulation, ∼30 minutes at the titrated intensity, and a 10-second ramp-down at the end of stimulation.

Eligibility criteria:
inclusion criteria: * patient undergoes four main clinical criteria for the diagnosis of rls according to the international restless leg syndrome study group (irlssg) including 1. an urge to move legs that is usually associated with paresthesia. 2. alleviation of the symptoms by moving the legs. 3. aggravation or exacerbation of the symptoms particularly at rest or during sitting or lying down in the bed. 4. worsening of the signs at night. patients with diagnosed with grade i and grade ii copd their ages ranged between 45-55 o all patients will be clinically and medically stable when attending the study exclusion criteria: * history of deep venous thrombosis * history of bleeding disorders * have an implantable device like a pacemaker * recent infected wound * history of allergic response to the electrodes, gel or tape * patients who participating in any other exercise program * loss of sensation or numbness
a study of olezarsen (formerly known as akcea-apociii-lrx) administered to adults with familial chylomicronemia syndrome (fcs) previously treated with volanesorsen

Conditions: Familial Chylomicronemia Syndrome

Summary: the purpose of the study is to evaluate the safety, tolerability, pharmacokinetic (pk) and pharmacodynamic (pd) effects of olezarsen (formerly known as akcea -apociii-lrx) in participants with fcs previously treated with volanesorsen.

this is a phase 3, multi-center, open-label safety study in 24 participants with fcs, previously treated with volanesorsen. the study consists of an 8- week screening period, treatment period up to week 209 and a 13-week follow-up period. participants enrolled will receive olezarsen every 4 weeks during the 209-week treatment period. treatment period was extended to allow participants to receive olezarsen for an additional 52 weeks for a total of a 209-week treatment period until the drug may be commercially available in the patient's country, or until the sponsor discontinues the olezarsen development program, whichever occurs earlier.

Eligibility criteria:
key inclusion criteria 1. participants with fcs (clinical or genetic diagnosis) currently on or previously treated with volanesorsen (isis 304801) o study participants in countries where waylivra® is commercially approved and available for participants should not be deprived of the treatment option with waylivra®. participation in this study for such participants will only be allowed when waylivra® was discontinued due to aes 2. the following concomitant medications will be allowed if dosing regimen is expected to remain constant through the end of the study (occasional or intermittent use of over-the-counter (otc) medications will be allowed at investigator's discretion): * statins, omega-3 fatty acids (prescription and otc), fibrates, or other lipid-lowering medications. participants taking otc omega-3 fatty acids should make every effort to remain on the same brand through the end of the study * antidiabetic medications * oral anticoagulants (e.g., dabigatran, rivaroxaban, or apixaban, and warfarin with regular clinical monitoring) * tamoxifen, estrogens or progestins key exclusion criteria: 1. treatment with another investigational drug (non-oligonucleotide), biological agent, or device within 4 weeks of screening, or 5 half-lives of investigational agent, whichever is longer 2. concomitant medication/procedure restrictions: 1. systemic corticosteroids or anabolic steroids within 6 weeks prior to screening and during the study unless approved by the sponsor medical monitor 2. plasma apheresis within 4 weeks prior to screening or planned during the study

Keywords: fcs